Get the Stockscreener App
12.30
2.07%
0.25
After Hours:
12.29
-0.01
-0.08%
Promis Neurosciences Inc stock is traded at $12.30, with a volume of 30,614.
It is up +2.07% in the last 24 hours and down -32.23% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$12.05
Open:
$12.47
24h Volume:
30,614
Relative Volume:
0.19
Market Cap:
$110.30M
Revenue:
-
Net Income/Loss:
$-39.72M
P/E Ratio:
-0.6701
EPS:
-18.3554
Net Cash Flow:
$-28.18M
1W Performance:
+14.95%
1M Performance:
-32.23%
6M Performance:
+3.14%
1Y Performance:
-12.14%
1-Day Range:
$12.05
$12.70
1-Week Range:
$10.63
$13.80
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
12.30 | 108.06M | 0 | -39.72M | -28.18M | -18.36 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference - TradingView — Track All Markets
Winners Losers: Is ProMIS Neurosciences Inc stock a hidden gem2026 Breakouts & Breakdowns & Weekly High Return Forecasts - baoquankhu1.vn
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan
Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc., Nippon Chemiphar - Mena FN
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can ProMIS Neurosciences Inc continue delivering strong returns2026 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Analysis Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
Janus Henderson (PMN) discloses 14.4% holding in PROMIS Neurosciences - Stock Titan
PMN Technical Analysis & Stock Price Forecast - Intellectia AI
Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn
Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView — Track All Markets
[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan
Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart
ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan
ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView
Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView
Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - ChartMill
Alzheimer's drug trial enrolls 144 patients with no serious side effects - Stock Titan
Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World
How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan
Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan
Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan
ProMIS Neurosciences to Present Data on ALS & Parkinsons - GlobeNewswire
ALS, Parkinson’s vaccine data to debut at leading AD/PD 2026 meeting - Stock Titan
ProMIS Neurosciences, Inc. (PMN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Abg V Siv X Ltd Net Worth (2026) - GuruFocus
Abg V Siv Ix Ltd Net Worth (2026) - GuruFocus
Sentiment Recap: Can ProMIS Neurosciences Inc. continue delivering strong returns2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Published on: 2026-03-10 05:13:34 - baoquankhu1.vn
PMN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Trade Report: Can ProMIS Neurosciences Inc continue delivering strong returnsJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc with Recent Share Purchase - GuruFocus
ProMIS Neurosciences (PMN) director purchases 2,000 common shares in open market - Stock Titan
Published on: 2026-03-05 21:52:27 - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc - GuruFocus
Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat
Eugene Williams Acquires 1,000 Shares of Promis Neurosciences (NASDAQ:PMN) Stock - MarketBeat
ProMIS Neurosciences, Inc. (PMN.TO) Competitors - Meyka
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):